2019
Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges.
Farge D, Frere C.
F1000 Research 2019, 8(F1000 Faculty Rev):97
The best direct-acting oral anticoagulant for treatment of venous thromboembolism?
Frere C, Farge D.
Lancet Haematol. 2018 Dec 14. pii: S2352-3026(18)30211-4. doi: 10.1016/S2352-3026(18)30211-4.
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges.
Frere C, Benzidia I, Marjanovic Z, Farge D.
Cancers (Basel). 2019 Jan 10;11(1). pii: E71. doi: 10.3390/cancers11010071.
Factors influencing patient’s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study.
Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N, Ghiringhelli F, Hamadé A, Vedrine L, Farge D. Support Care Cancer. 2019 May 1. doi: 10.1007/s00520-019-04815-z. [Epub ahead of print]
Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE database.
Fuentes HE, Tafur AJ, Caprini JA, Alatri A, Trujillo-Santos J, Farge-Bancel D, Rosa V, Font L, Vilaseca A, Monreal M; RIETE Investigators.
Int Angiol. 2019 May 16. doi: 10.23736/S0392-9590.19.04110-5
2018
Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018?
Frere C, Farge D.
J Med Vasc. 2018 Sep;43(5):293-301.
Edoxaban for Cancer-Associated Venous Thromboembolism.
Frere C, Dufilho M.
N Engl J Med. 2018 Jul 5;379(1):94. doi: 10.1056/NEJMc1806646.
Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, Védrine L, Bensalha H, Bonnet I, Péré-Vergé D, Coudurier M, Li V, Rafii H, Benzidia I, Connors JM,* and Resche-Rigon M.
Oncotarget. 2018; 9:26990-26999.
Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
Frere C, Trujillo-Santos J, Font C, Sampériz Á, Quintavalla R, González-Martínez J, Vázquez FJ, Lima J, Farge D, Monreal M; RIETE Investigators.
Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.
Venous thromboembolism and pancreatic cancer.
Frere C, Bournet B, Benzidia I, Jamelot M, Debourdeau P, Hij A, Rafii-Elayoubi A, Buscail L, Farge D, pour le Groupe francophone thrombose et cancer.
J Med Vasc. 2018 doi: 10.1016/j.jdmv.2018.05.003
Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.
Kuperman A, Lopez-Reyes R, Bosco LJ, Lorenzo A, Jose B, Farge-Bancel D, Alfonso M, Lumbierres M, Stemer G, Monreal Bosch M, Braester A; RIETE Investigators.
J Thromb Thrombolysis. 2018 Jan 30. doi: 10.1007/s11239-018-1610-9.
Risk of Arterial Thrombosis in Cancer Patients: Which Role for Cancer Therapies Vascular Toxicities?
Frere C, Martin-Toutain I, Thuny F, Bonello L.
J Am Coll Cardiol. 2018 Jan 16;71(2):260. doi: 10.1016/j.jacc.2017.10.087
2017
New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application.
Benzidia I, Connault J, Solanilla A, Michon-Pasturel U, Jamelot M, Nguessan MK, Hij A, Le Maignan C, Farge D, Frère C; pour le Groupe Francophone Thrombose et Cancer.
J Med Vasc. 2017 Dec;42(6):375-383. doi:10.1016/j.jdmv.2017.09.006
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.
Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, Desseaux K, Kalidi I, Villiers S, Giachetti S, Frere C, Farge D.
Cancer Med. 2017 Oct 4. doi: 10.1002/cam4.1201.
Implementation of international good clinical practice guidelines to improve care of patients with cancer-related venous thromboembolism.
Qari R, Frere C, Farge D, El Ayoubi Hanadi.
Appl Hematol 2017;8:85-98.
Women, thrombosis, and cancer: A gender-specific analysis.
Farge D, Bounameaux H, Bauersachs RM, Brenner B.
Thromb Res 2017 Mar;151(Suppl 1):S21-9.
The clinical course of venous thromboembolism may differ according to cancer site.
Mahé I, Chidiac J, Bertoletti L, Trujillo-Santos J, Peris M, Pérez Ductor C, Niete S, Grandone E, Monreal M; RIETE investigators.
Am J Med 2017 Mar;130(3):337-47.
Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.
Trujillo-Santos J, Martos FM, Font C, Farge-Bancel D, Rosa V, Lorenzo A, Barrón M, Lorente MA, Pedrajas JM, Monreal M.
Heliyon 2017 Jan 16;3(1):e00229.
Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey.
Agzarian J, Linkins LA, Schneider L, Hanna WC, Finley CJ, Schieman C, De Perrot M, Crowther M, Douketis J, Shargall Y.
J Thorac Dis 2017 Jan;9(1):80-7.
The application of current proposed venous thromboembolism risk assessment model for ambulatory patients with cancer.
Abdel-Razeq H, Mansour A, Saadeh SS, Abu-Nasser M, Makoseh M, Salam M, Abufara A, Ismael Y, Ibrahim A, Khirfan G, Ibrahim M.
Clin Appl Thromb Hemost 2017 Jan 1.
2016
Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial.
Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY.
J Clin Oncol 2016 Dec 28.
Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism.
Peris M, Jiménez D, Maestre A, Font C, Tafur AJ, Mazzolai L, Xifre B, Skride A, Dentali F, Monreal M; RIETE investigators.
Eur Respir J 2016 Nov;48(5):1360-8.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A.
Lancet Oncol 2016 Oct;17(10):e452-66.
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
Bach M, Bauersachs R.
Thromb Haemost 2016 Sep 28;116(Suppl 2):S24-32.
Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study.
Cajfinger F, Debourdeau P, Lamblin A, Benatar V, Falvo N, Benhamou Y, Sevestre MA, Farge-Bancel D; TROPIQUE investigators.
Thromb Res 2016 Aug;144:85-92.
LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs R.
Thromb Res 2016 Apr;140(Suppl 1):S160-4.
ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M, Kleinjan A, Hajage D, Büller HR, Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A, Mahe I.
J Thromb Haemost 2016 Feb;14(2):306-15.
2015
Farge D, Trujillo-Santos J, Debourdeau P, Bura-Riviere A, Rodriguez-Beltrán EM, Nieto JA, Peris ML, Zeltser D, Mazzolai L, Hij A, Monreal M; RIETE Investigators.
Medicine (Baltimore) 2015 Aug;94(32):e1235.
Global public awareness of venous thromboembolism.
Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G; ISTH Steering Committee for World Thrombosis Day.
J Thromb Haemost 2015 Aug;13(8):1356-71.
Editorial: Comorbidity and the risk of venous thromboembolism in prostate cancer.
Alibhai SMH, O’Neill ME.
2015 Jun.
Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?
Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, Ballaz A, Hernàndez Blasco LM, Marchena PJ, Monreal M; RIETE investigators.
PLoS One 2015 Jun;10(6):e0128741.
Duration of anticoagulation after venous thromboembolism in real world clinical practice.
Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M; RIETE investigators.
Thromb Res 2015 Apr;135(4):666-72.
Guidelines for the management of cancer and thrombosis - Special aspects in women.
Bauersachs R.
Thromb Res 2015 Feb;135(Suppl 1):S16-22.
2014
Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH.
Khorana AA, Otten HM, Zwicker JI, Connolly GC, Bancel DF, Pabinger I; Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis.
J Thromb Haemost 2014 Nov;12:1928-31.
Implementing thrombosis guidelines in cancer patients: A review.
Farge-Bancel D, Bounameaux H, Brenner B, Büller HR, Kakkar A, Pabinger I, Streiff M, Debourdeau P.
Rambam-Maimonides Med J 2014 Oct;5(4):e0041.
2013
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.
Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H.
J Thromb Haemost 2013 Jan;11(1):71-80.
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.
J Thromb Haemost 2013 Jan;11(1):56-70.
2009
Venous thromboembolism prophylaxis and treatment in cancer: A consensus statement of major guidelines panels and call to action.
Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.
J Clin Oncol 2009 Oct;27(29):4919-26.